As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company’s Phase 1 NOXCOVID-1 study.
Pfizer and BioNTech announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.
Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.
Blade Therapeutics announced that the Phase 2 clinical study of the company’s investigational therapeutic, BLD-2660, has enrolled half of the anticipated 120 coronavirus disease-19 (COVID-19) pneumonia patients.
Ridgeback Biotherapeutics has commenced enrolment for the phase 2 trial of its Covid-19 drug candidate EIDD-2801, an orally-bioavailable form of a potent ribonucleoside analog.
Theravance Biopharma has dosed the first patient in the phase 2 study of lung-selective and nebulized Janus kinase inhibitor (JAKi) TD-0903 to treat hospitalised patients with acute lung injury (ALI) due to Covid-19.
Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer.
Artugen Therapeutics Limited, a Company developing novel live biotherapeutics (LBPs) for patients living with infectious, inflammatory and oncologic diseases announced today the first patient dosed with ART24, the Company’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection (CDI).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.